Wikipedia:Articles for deletion/Hemispherx Biopharma

The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.

The result was keep. (non-admin closure) Lourdes 16:35, 25 July 2018 (UTC)[reply]

Hemispherx Biopharma

[Hide this box] New to Articles for deletion (AfD)? Read these primers!

Hemispherx Biopharma (edit | talk | history | protect | delete | links | watch | logs | views) – (View log · Stats)
(Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL)

Fails WP:GNG. Google News archive reveals only press releases. Sources cited in article lack depth. See WP:ORGDEPTH. See also Wikipedia:Articles for deletion/Oragen. Daask (talk) 15:55, 11 July 2018 (UTC)[reply]

Note: This discussion has been included in the list of Organizations-related deletion discussions. Hhkohh (talk) 16:01, 11 July 2018 (UTC)[reply]
Note: This discussion has been included in the list of Companies-related deletion discussions. Hhkohh (talk) 16:01, 11 July 2018 (UTC)[reply]
Note: This discussion has been included in the list of Florida-related deletion discussions. Hhkohh (talk) 16:01, 11 July 2018 (UTC)[reply]
Note: This discussion has been included in the list of Science-related deletion discussions. Agricolae (talk) 16:07, 11 July 2018 (UTC)[reply]
Note: This discussion has been included in the list of Technology-related deletion discussions. Agricolae (talk) 16:07, 11 July 2018 (UTC)[reply]
Note: This discussion has been included in the list of United States of America-related deletion discussions. Agricolae (talk) 16:07, 11 July 2018 (UTC)[reply]
Note: This discussion has been included in the list of Medicine-related deletion discussions. Agricolae (talk) 16:07, 11 July 2018 (UTC)[reply]
  • Redirect to Rintatolimod - All of the coverage of this company is either WP:ROUTINE, or relates to what appears to be its sole product, the drug Ampligen® (generic name Rintatolimod). The company's role with their drug is already sufficiently documented on that page, and I don't see any coverage that would suggest the company is notable outside of their role with the drug, so I would suggest an analogy to WP:ONEEVENT applies. It is likely anyone who searches for the company's name is interested, one way or another, in the information presented on the drug's page, so a redirect seems the best way to go. Agricolae (talk) 16:19, 11 July 2018 (UTC)[reply]
  • Keep per the significant coverage in multiple independent reliable sources.

    From Wikipedia:Notability (organizations and companies)#Publicly traded corporations (my bolding):

    There has been considerable discussion over time whether publicly traded corporations, or at least publicly traded corporations listed on major stock exchanges such as the NYSE and other comparable international stock exchanges, are inherently notable. Consensus has been that notability is not automatic in this (or any other) case. However, sufficient independent sources almost always exist for such companies, so that notability can be established using the primary criterion discussed above. Examples of such sources include independent press coverage and analyst reports. Accordingly, article authors should make sure to seek out such coverage and add references to such articles to properly establish notability.



    Analyst reports

    1. Mahajan, Snehal (2015-04-13). "13 April 2015: Diligence and Valuation Report: Hemisphere Biopharma, Inc". Arrowhead Business and Investment Decisions. Archived from the original on 2018-07-12. Retrieved 2018-07-12.

      This is a 26-page analyst report about the company.

      The report says:

      Any opinions expressed in this report are statements of Arrowhead BID’s judgment to this date and are subject to change without notice.

      This report was prepared for general circulation and does not provide investment recommendations specific to individual investors. As such, any of the financial or other money-management instruments linked to the Company and Company valuation described in this report, hereafter referred to as “the securities”, may not be suitable for all investors.

      Investors must make their own investment decisions based upon their specific investment objectives and financial situation utilizing their own financial advisors as they deem necessary.

      The report has a business overview section with these subsections:
      1. Product Offerings
      2. Company Premiums
        1. Alferon N Injection®
        2. Ampligen®
        3. Alferon® LDO (Low Dose Oral)
      3. Company Risks
      4. Corporate Strategy
      5. Shareholding Pattern
      6. Listing and Contact Details
      Here is the company overview:

      Company Overview: Based in Philadelphia, Pennsylvania, Hemispherx Biopharma Inc. (hereinafter referred to as “Hemispherx” or “the Company”) is a specialty pharmaceutical company primarily engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company has two flagship products, 1) Alferon N Injection® - approved for a category of STD infections; 2) Ampligen® - an experimental Ribonucleic Acid developed to treat viral diseases and disorders of the immune system, specifically Chronic Fatigue Syndrome (CFS). The Company is also developing an oral formulation of Alferon N, Alferon® LDO (Low Dose Oral), for treating Influenza. The Company has formed collaborations with many research laboratories to examine if Ampligen® and/or Alferon® exhibits antiviral activity against the Ebola virus & testing Ampligen® in humans in conjunction with a nasal flu vaccine. The Company owns and exclusively operates a Good Manufacturing Practice manufacturing facility in New Jersey.

      The analyst report lists five categories of company risks and provides a paragraph of discussion for each: (1) Unsuccessful Product Development, (2) Uncertainty related to regulatory approval, (3) Cash Flow Uncertainty, (4) Inadequate financial resources/Delay in Commercialization, (5) Reduction in the Incidence of Ebola Cases.
    2. Bansal, Abhishek (2015-09-29). "29 September 2015: Diligence and Valuation Report: Hemisphere Biopharma, Inc" (PDF). Arrowhead Business and Investment Decisions. Archived from the original (PDF) on 2018-07-12. Retrieved 2018-07-12.

      This is another analyst report from Arrowhead Business and Investment Decisions.

    3. This 3 October 2014 articlearchive.is from StreetInsider notes:

      Chardan Capital affirms its Buy rating and $3 price target on Hemispherx BioPharma (AMEX: HEB) following a recent company update and expanded Ebola collaborations.

      Analyst Ling Wang offered the following commentary:

      HEB expanded research on potential Ebola treatments to five Institutional collaborators. The five collaborators include National Institutes of Allergy and Infectious Disease (NIAID); a branch of the NIH; the United States Army Research Institute in Infectious Disease (USAMRIID); the Swiss Department of Defense (Spiez Lab); Howard University, Washington, DC; and a US-based facility with biosafety

      level 4 (BSL-4) capabilities with whom a Sponsor Research Agreement is currently being negotiated. Recall HEB has previously announced a collaboration with the USAMRIID for exploring Alferon against the deadly Ebola virus.

      [Several more paragraphs.]

    4. This articleWebCite from the company notes:

      Philadelphia, PA, Thursday, September 09, 2004: Griffin Securities announced today that it has initiated research coverage of Hemispherx Biopharma (AMEX: HEB - News) with a Buy Rating and a 12-month price target of $9.19. Chrystyna Bedrij, Director of Research, issued the report.

      This is an analyst report from Griffin Securities about Hemisphere Biopharma.
    5. This forum postWebCite from boursorama.com provides information from a Maxim Group analyst report written by analyst Yale Jen and published in April 2011.
    There is sufficient coverage in reliable sources to allow Hemisphere Biopharma to pass Wikipedia:Notability#General notability guideline, which requires "significant coverage in reliable sources that are independent of the subject".

    Cunard (talk) 07:53, 12 July 2018 (UTC)[reply]

  • There is enough coverage about Hemispherx Biopharma's history, products (Alferon N Injection®, Ampligen®, and Alferon®), premiums, and risks to justify a separate article from Rintatolimod (Ampligen), one of its products.

    Cunard (talk) 07:53, 12 July 2018 (UTC)[reply]

  • Keep As per Cunard's analyst reports, meets the criteria for establishing notabilty, passes WP:NCORP. HighKing++ 16:33, 16 July 2018 (UTC)[reply]
Relisted to generate a more thorough discussion and clearer consensus.
Please add new comments below this notice. Thanks, North America1000 09:45, 18 July 2018 (UTC)[reply]
  • Keep. Meets WP:CORP with Cunard's analyst reports. — Newslinger talk 12:23, 20 July 2018 (UTC)[reply]
The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Wikipedia:Articles_for_deletion/Hemispherx_Biopharma&oldid=852205121"